iBio
iBio
IBIO
NYSE
5.28
USD
-4.86%
About
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases.
Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8.
IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 81.1K |
| Three Month Average Volume | 1.9M |
| High Low | |
| Fifty-Two Week High | 8.568 USD |
| Fifty-Two Week Low | 1.0214 USD |
| Fifty-Two Week High Date | 14 Sep 2023 |
| Fifty-Two Week Low Date | 18 Jan 2024 |
| Price and Volume | |
| Current Price | 1.97 USD |
| Beta | -3 |
| Relative Price Change | |
| Four Week Relative Price Change | -5.34% |
| Thirteen Week Relative Price Change | -22.66% |
| Twenty-Six Week Relative Price Change | 44.49% |
| Fifty-Two Week Relative Price Change | -73.97% |
| Year-to-Date Relative Price Change | 21.43% |
| Price Change | |
| One Day Price Change | 5.35% |
| Thirteen Week Price Change | -17.23% |
| Twenty-Six Week Price Change | 58.87% |
| Five Day Price Change | -2.96% |
| Fifty-Two Week Price Change | -67.38% |
| Year-to-Date Price Change | 43.80% |
| Month-to-Date Price Change | -3.90% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 15.14623 USD |
| Book Value Per Share (Most Recent Quarter) | 2.91907 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 9.84047 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 2.28824 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -9.04079 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.02622 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -47.87423 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -13.09512 USD |
| Normalized (Last Fiscal Year) | -46.95141 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -47.87423 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -13.09512 USD |
| Including Extraordinary Items (Last Fiscal Year) | -106.1821 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -17.08635 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 4.23535 USD |
| Cash Per Share (Most Recent Quarter) | 0.62249 USD |
| Cash Flow Per Share (Last Fiscal Year) | -46.20171 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -8.4844 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -10.05605 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1,905 |
| Cash Flow Revenue (Trailing Twelve Months) | -38,352 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -34,258.00% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -1,467.30% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -36,380.00% |
| Operating Margin (5 Year) | -1,516.14% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -34,258.00% |
| Net Profit Margin (5 Year) | -1,467.30% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -50.39% |
| Tangible Book Value (5 Year) | -7.23% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 42.90% |
| Total Debt (5 Year) | -11.06% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 92.55% |
| EPS Change (Trailing Twelve Months) | 81.79% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 9.1M |
| Net Debt (Last Fiscal Year) | 9.7M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | 340 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 4 |
| Long Term Debt to Equity (Most Recent Quarter) | 4 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -36,866,000 |
| Free Cash Flow (Trailing Twelve Months) | -19,176,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 91 |
| Total Debt to Equity (Most Recent Quarter) | 58 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -41.69% |
| Return on Assets (Trailing Twelve Months) | -36.24% |
| Return on Assets (5 Year) | -28.09% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -74.33% |
| Return on Equity (Trailing Twelve Months) | -81.08% |
| Return on Equity (5 Year) | -56.09% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -66.17% |
| Return on Investment (Trailing Twelve Months) | -67.39% |
| Return on Investment (5 Year) | -32.63% |